Document:

Exhibit 10.2

                                Amendment to All
                       Outstanding Stock Option Agreements
                    under the 1997 Long-Term Incentive Plan
                    ---------------------------------------

      Effective August 5, 2005, Section 3(b)(iii) of each outstanding Stock
Option Agreement under the 1997 Long-Term Incentive Plan was amended to read in
its entirety as follows:

           (iii) LabOne merges or consolidates with another corporation or other
      entity, unless such merger of consolidation (A) is approved by a majority
      of the Continuing Directors of LabOne, and (B) is specifically designated
      by a majority of the Continuing Directors not to constitute a change of
      control for purposes of the Plan; orExhibit 10.3
                               AMENDMENT NO. 1 TO

                             STOCK OPTION AGREEMENT

                                 pursuant to the

                                  LABONE, INC.

                          1997 LONG-TERM INCENTIVE PLAN

      This AMENDMENT No. 1 TO STOCK OPTION AGREEMENT ("Amendment") is dated as
of _____________ and entered into by and between LabOne, Inc. ("LabOne"), a
Missouri corporation, and _____________________ ("Optionee").

      WITNESSETH that:

      WHEREAS, LabOne and the Optionee are parties to one or more Stock Option
Agreements relating to stock options granted under the LabOne, Inc. 1997
Long-Term Incentive Plan (the "Plan") that are not fully vested as of the date
hereof (individually the "Stock Option Agreement" or collectively the "Stock
Option Agreements"); and

      WHEREAS, LabOne and the Optionee desire to amend the Stock Option
Agreements to provide that such stock options shall become fully exercisable
upon consummation of a merger or consolidation of LabOne with another
corporation rather than upon shareholder approval of such a transaction; and

      WHEREAS, it is in the best interests of LabOne and the Optionee to make
such change in order for LabOne to be able to engage in one or more corporate
transactions;

      NOW, THEREFORE, in consideration of the terms and provisions of this
Amendment and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged by the parties hereto, the parties hereto agree
as follows:

      Section 1. Section 3(b)(iii) of each outstanding Stock Option Agreement is
hereby amended to read as follows:

      (iii)  LabOne merges or consolidates with another corporation or other
      entity, unless such merger of consolidation (A) is approved by a majority
      of the Continuing Directors of LabOne, and (B) is specifically designated
      by a majority of the Continuing Directors not to constitute a change of
      control for purposes of the Plan; or

      Section 2.The remaining provisions of each Stock Option Agreement shall
apply to this Amendment and to such Stock Option Agreement as amended by this
Amendment.

                                        -1-
<PAGE>

      IN WITNESS WHEREOF, LabOne, Inc. has caused this Amendment to be executed
in its corporate name, and the Optionee has executed the same in evidence of the
Optionee's acceptance hereof, upon the terms and conditions herein set forth, as
of the day and year first above written.

                               LABONE, INC.

                               By:
                                  ----------------------------
                                     Name:
                                     Title:

                               ----------------------------
                               Optionee

                                        -2-Exhibit 10.4

                                  Amendments to
                          2001 Long-Term Incentive Plan
                          -----------------------------

      1. Effective August 5, 2005, the LabOne, Inc. 2001 Long-Term Incentive
 Plan was amended as follows:

      a. Section 2.5.9 of the 2001 Long-Term Incentive Plan was amended to read
      as follows:

          In the  event  that the  Board  approves  (a) the  merger or
          consolidation of LabOne with or into another  corporation or
          other entity in which the shareholders of LabOne immediately
          prior to such  transaction  will  beneficially own no voting
          securities or voting securities  possessing less than 50% of
          the combined voting power of the then outstanding securities
          of the surviving entity in such transaction (or its parent),
          excluding  for  purposes  of  such   calculation   any  such
          shareholder  of LabOne  who  beneficially  owns prior to the
          transaction  more than ten percent (10%) of the other entity
          involved in the transaction  (or its parent),  (b) a sale of
          all or  substantially  all of the  assets of LabOne in which
          outstanding   securities   of  LabOne  are   exchanged   for
          securities,  cash or other  property of any  corporation  or
          other entity or (c) a liquidation  or  dissolution of LabOne
          (collectively, a "Corporate Transaction");  the Board may in
          its  sole   discretion   prior  to   consummation   of  such
          transaction  take any one or more of the  following  actions
          with respect to outstanding stock options granted under this
          Program:  (i)  provide  that  such  stock  options  shall be
          assumed or equivalent  stock options shall be substituted by
          the  acquiring or  succeeding  corporation  or entity (or an
          affiliate  thereof)  or (ii) upon  thirty  (30) days'  prior
          written  notice  to the  Optionee,  provide  that the  stock
          option shall be exercisable  in full and shall  terminate at
          the end of such  thirty  (30) day  period to the  extent not
          exercised by such time, at the end of which period the stock
          option  shall  terminate;  provided,  however,  that  unless
          determined  otherwise  by the  Board,  the  acceleration  of
          vesting,  exercise (if such stock option is  exercised)  and
          termination  of such stock option under clause (ii) shall be
          subject  to the  condition  that  the  respective  Corporate
          Transaction  shall be consummated  and such  acceleration of
          vesting,  exercise (if such stock option is  exercised)  and
          subsequent   termination  of  such  stock  option  shall  be
          effective  immediately  prior  to the  effectiveness  of the
          respective Corporate Transaction.

     b. Section 3.5.7 of the 2001 Long-Term Incentive Plan was amended to read
     as follows:

          Effect of Certain  Transactions on Formula  Options.  In the
          event   that  the   Board   approves   (a)  the   merger  or
          consolidation of LabOne with or into another  corporation or
          other entity in which the shareholders of LabOne

<PAGE>

          immediately  prior to such transaction will beneficially own
          no voting  securities or voting  securities  possessing less
          than  50%  of  the   combined   voting  power  of  the  then
          outstanding  securities  of the  surviving  entity  in  such
          transaction (or its parent),  excluding for purposes of such
          calculation any such  shareholder of LabOne who beneficially
          owns prior to the transaction more than ten percent (10%) of
          the  other  entity  involved  in  the  transaction  (or  its
          parent),  (b) a  sale  of all  or  substantially  all of the
          assets of LabOne in which  outstanding  securities of LabOne
          are exchanged for securities,  cash or other property of any
          corporation   or  other  entity  or  (c)  a  liquidation  or
          dissolution   of   LabOne   (collectively,    a   "Corporate
          Transaction"); the Board may in its sole discretion prior to
          consummation of such transaction take any one or more of the
          following  actions  with  respect  to  outstanding   Formula
          Options:  (i)  provide  that such  Formula  Option  shall be
          assumed or an equivalent  stock option shall be  substituted
          by the acquiring or succeeding  corporation or entity (or an
          affiliate  thereof)  or (ii) upon  thirty  (30) days'  prior
          written  notice to an Eligible  Director,  provide  that the
          Formula  Option  shall  be  exercisable  in full  and  shall
          terminate  at the end of such  thirty (30) day period to the
          extent  not  exercised  by such  time,  at the end of  which
          period  the  Formula  Option  shall   terminate;   provided,
          however,  that unless determined otherwise by the Board, the
          acceleration of vesting, exercise (if such Formula Option is
          exercised)  and  termination  of such  Formula  Option under
          clause  (ii)  shall be  subject  to the  condition  that the
          respective  Corporate  Transaction  shall be consummated and
          such  acceleration  of vesting,  exercise  (if such  Formula
          Option is  exercised)  and  subsequent  termination  of such
          Formula Option shall be effective  immediately  prior to the
          effectiveness of the respective Corporate Transaction.Exhibit 10.5

                                  Amendments to
                       Outstanding Stock Option Agreements
                     under the 2001 Long-Term Incentive Plan
                     ---------------------------------------

      1.  Effective August 5, 2005, Section 2.5.9 of each outstanding Stock
Option Agreement under the Bonus Replacement Stock Option Program of the LabOne,
Inc. 2001 Long-Term Incentive Plan was amended to read in its entirety as
follows:

          In the  event  that the  Board  approves  (a) the  merger or
          consolidation of LabOne with or into another  corporation or
          other entity in which the shareholders of LabOne immediately
          prior to such  transaction  will  beneficially own no voting
          securities or voting securities  possessing less than 50% of
          the combined voting power of the then outstanding securities
          of the surviving entity in such transaction (or its parent),
          excluding  for  purposes  of  such   calculation   any  such
          shareholder  of LabOne  who  beneficially  owns prior to the
          transaction  more than ten percent (10%) of the other entity
          involved in the transaction  (or its parent),  (b) a sale of
          all or  substantially  all of the  assets of LabOne in which
          outstanding   securities   of  LabOne  are   exchanged   for
          securities,  cash or other  property of any  corporation  or
          other entity or (c) a liquidation  or  dissolution of LabOne
          (collectively, a "Corporate Transaction");  the Board may in
          its  sole   discretion   prior  to   consummation   of  such
          transaction  take any one or more of the  following  actions
          with respect to outstanding stock options granted under this
          Program:  (i)  provide  that  such  stock  options  shall be
          assumed or equivalent  stock options shall be substituted by
          the  acquiring or  succeeding  corporation  or entity (or an
          affiliate  thereof)  or (ii) upon  thirty  (30) days'  prior
          written  notice  to the  Optionee,  provide  that the  stock
          option shall be exercisable  in full and shall  terminate at
          the end of such  thirty  (30) day  period to the  extent not
          exercised by such time, at the end of which period the stock
          option  shall  terminate;  provided,  however,  that  unless
          determined  otherwise  by the  Board,  the  acceleration  of
          vesting,  exercise (if such stock option is  exercised)  and
          termination  of such stock option under clause (ii) shall be
          subject  to the  condition  that  the  respective  Corporate
          Transaction  shall be consummated  and such  acceleration of
          vesting,  exercise (if such stock option is  exercised)  and
          subsequent   termination  of  such  stock  option  shall  be
          effective  immediately  prior  to the  effectiveness  of the
          respective Corporate Transaction.

      2.  Effective August 5, 2005, a new Section 2.5.9A was added to each
outstanding Stock Option Agreement under the Bonus Replacement Stock Option
Program of the LabOne, Inc. 2001 Long-Term Incentive Plan, to read in its
entirety as follows:

          In the event that this stock option is exercised pursuant to
          clause (ii) of Section 2.5.9 in connection  with a Corporate
          Transaction  in which  shares of common  stock of LabOne are
          converted into the right to receive cash,

<PAGE>

          unless the Optionee  elects in writing at the time the stock
          option is exercised pursuant to clause (ii) of Section 2.5.9
          to  receive  the  Shares  issuable  upon  exercise,  (a) the
          Optionee will be entitled to receive upon  effectiveness  of
          such exercise, in lieu of Shares issuable in connection with
          such exercise of the stock  option,  an amount in cash equal
          to  the  number  of  Shares  subject  to  the  stock  option
          immediately prior to such exercise  multiplied by the amount
          by which the cash  consideration  per Share  payable in such
          Corporate  Transaction exceeds the exercise price per Share,
          subject  to all  applicable  federal,  state  and  local tax
          withholding requirements,  and (b) the Optionee shall not be
          required to pay the exercise  price in connection  with such
          exercise.

      3.  Effective August 5, 2005, Section 8 of each outstanding Stock Option
Agreement pursuant to the Stock Program for Outside Directors and each
outstanding Stock Option Agreement pursuant to the Stock Incentive Program under
the LabOne, Inc. 2001 Long-Term Incentive Plan was amended to read in its
entirety as follows:

          In the event that the Board of Directors of LabOne  approves
          (a) the  merger  or  consolidation  of  LabOne  with or into
          another   corporation   or  other   entity   in  which   the
          shareholders of LabOne immediately prior to such transaction
          will   beneficially  own  no  voting  securities  or  voting
          securities  possessing  less than 50% of the combined voting
          power of the then  outstanding  securities  of the surviving
          entity in such  transaction  (or its parent),  excluding for
          purposes of such  calculation any such shareholder of LabOne
          who beneficially owns prior to the transaction more than ten
          percent   (10%)  of  the  other   entity   involved  in  the
          transaction   (or  its  parent),   (b)  a  sale  of  all  or
          substantially   all  of  the   assets  of  LabOne  in  which
          outstanding   securities   of  LabOne  are   exchanged   for
          securities,  cash or other  property of any  corporation  or
          other entity or (c) a liquidation  or  dissolution of LabOne
          (collectively,  a  "Corporate  Transaction");  the  Board of
          Directors  of  LabOne  may in its sole  discretion  prior to
          consummation of such transaction take any one or more of the
          following  actions with  respect to the Option:  (i) provide
          that the  Option  shall be assumed  or an  equivalent  stock
          option shall be  substituted  by the acquiring or succeeding
          corporation or entity (or an affiliate thereof) or (ii) upon
          thirty  (30) days'  prior  written  notice to the  Optionee,
          provide  that the Option  shall be  exercisable  in full and
          shall terminate at the end of such thirty (30) day period to
          the extent not  exercised by such time,  at the end of which
          period the Option shall terminate;  provided,  however, that
          unless  determined  otherwise by the Board, the acceleration
          of  vesting,  exercise  (if such  Option is  exercised)  and
          termination  of such  Option  under  clause  (ii)  shall  be
          subject  to the  condition  that  the  respective  Corporate
          Transaction  shall be consummated  and such  acceleration of
          vesting,   exercise  (if  such  Option  is  exercised)   and
          subsequent  termination  of such Option  shall be  effective
          immediately  prior to the  effectiveness  of the  respective
          Corporate Transaction.

<PAGE>

      4.  Effective August 5, 2005, a new Section 8A was added to each
outstanding Stock Option Agreement pursuant to the Stock Program for Outside
Directors and each outstanding Stock Option Agreement pursuant to the Stock
Incentive Program under the LabOne, Inc. 2001 Long-Term Incentive Plan, to read
in its entirety as follows:

          In the event  that  this  Option is  exercised  pursuant  to
          clause  (ii) of  Section 8 in  connection  with a  Corporate
          Transaction  in which  shares of common  stock of LabOne are
          converted  into  the  right  to  receive  cash,  unless  the
          Optionee  elects  in  writing  at the  time  the  Option  is
          exercised  pursuant  to clause  (ii) of Section 8 to receive
          the Shares issuable upon exercise,  (a) the Optionee will be
          entitled to receive upon effectiveness of such exercise,  in
          lieu of Shares  issuable in connection with such exercise of
          the Option,  an amount in cash equal to the number of Shares
          subject to the  Option  immediately  prior to such  exercise
          multiplied by the amount by which the cash consideration per
          Share  payable in such  Corporate  Transaction  exceeds  the
          exercise price per Share, subject to all applicable federal,
          state and local tax  withholding  requirements,  and (b) the
          Optionee  shall not be required to pay the exercise price in
          connection with such exercise.

      5.  Effective August 5, 2005, Section 3(b)(iii) of each outstanding Stock
Option Agreement pursuant to the Stock Incentive Program under the LabOne, Inc.
2001 Long-Term Incentive Plan was amended to read in its entirety as follows:

          (iii)LabOne merges or consolidates with another  corporation
          or other entity,  unless such merger of consolidation (A) is
          approved  by a  majority  of  the  Continuing  Directors  of
          LabOne, and (B) is specifically  designated by a majority of
          the  Continuing  Directors  not to  constitute  a change  of
          control for purposes of the Plan; or

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00088-of-00352.parquet"}]]